Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer Eliminates Roadblock To Remicade Biosimilar Launch

Executive Summary

October launch seems more certain after district court rules patent covering the antibody is invalid; litigation continues over cell culture media patent that expires in 2027.


Related Content

How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
Pfizer's Remicade Biosimilar: Sept. 15 Is Earliest Launch Date


Related Companies